HOME >> BIOLOGY >> NEWS
Nuclear medicine patients: No-alarm holiday travel tips

RESTON, Va. -- Traveling during the holidays--especially for the nearly 60,000 individuals who daily undergo a nuclear medicine treatment or test in this country--will go smoother if medical professionals advise their patients to follow some simple tips from SNM, the leading international molecular imaging and nuclear medicine society.

"Due to heightened concerns about terrorism, sensitive radiation detectors are used in some major cities and in public transportation facilities," explained SNM President Martin P. Sandler. "Occasionally, a patient who has had a nuclear medicine procedure may be stopped by security personnel because he or she may trigger the alarm on a radiation detector. On rare occasions, this could cause long delays, interrogation and body searches," added Sandler, who speaks for 16,000 physician, technologist and scientist members of the international scientific and professional society.

Nuclear medicine, which is broadening its scope to include molecular imaging, involves using tiny amounts of radioactive materials in patients to examine molecular processes in the body. These procedures can be used to detect and evaluate heart disease, cancer, brain disorders and stress fractures. Commonly performed procedures include positron emission tomography (PET) scans to diagnose and monitor treatment in cancer, cardiac stress tests to analyze heart function, bone scans to detect orthopedic injuries and lung scans blood clots.

Although the material used for these procedures is minute and soon loses its radioactivity, it may take time before a patient stops emitting detectable levels of radiation. The sensing devices used today at security screening points are extremely sensitive. "Residual radiation from medical treatments may cause travel delays due to increased security scanning at places such as airport boarding areas, rail stations, ports, international border crossings, bridges, tunnels and large public gatherings,"
'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-652-6773
Society of Nuclear Medicine
9-Nov-2006


Page: 1 2 3

Related biology news :

1. Journal of Nuclear Medicines impact grows, remains consistently high over past 5 years
2. Depiction of findings selected as 2007 Image of the Year by Society for Nuclear Medicine
3. SNM recognizes R. Edward Coleman with 2007 Georg Charles de Hevesy Nuclear Pioneer Award
4. Journal of Nuclear Medicine releases new research faster
5. PET/CT in Cancer Patient Management examined in Journal of Nuclear Medicine Supplement
6. Society of Nuclear Medicine offers free access to Journal of Nuclear Medicine
7. Journal of Nuclear Medicine publishes NCI-sponsored guidelines for using FDG PET
8. SNM recognizes contributions of Walter Wolf with 2006 Georg Charles de Hevesy Nuclear Pioneer Award
9. SNM awards $25,000 Mallinckrodt Seed Grant in Molecular Imaging/Nuclear Medicine Research
10. Nuclear medicine imaging allows prediction of breast cancer patients response to hormonal treatment
11. Society of Nuclear Medicine commends FDA for release of new guidance documents

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nuclear medicine patients alarm holiday travel tips

(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: